XML 65 R56.htm IDEA: XBRL DOCUMENT v3.25.3
Liability Related to the Sale of Future Royalties and Milestones (Narrative) (Details) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 9 Months Ended
Jan. 19, 2018
May 31, 2024
Sep. 30, 2025
Dec. 31, 2024
Liability Related To Sale Of Future Royalties And Milestones [Line Items]        
Non-cash royalty revenue recognized     $ 77,535  
Non-cash interest expense     36,243  
Fair value of the Purchaser Upsize Option       $ 69
HCR [Member] | GSK Agreements [Member] | Royalty Purchase Agreement [Member]        
Liability Related To Sale Of Future Royalties And Milestones [Line Items]        
Percentage of purchase of worldwide rights to receive royalties 100.00%      
Gross proceeds received for royalty rights $ 190,000      
Non-cash royalty revenue recognized     77,500  
Non-cash interest expense     $ 23,000  
Effective annual interest rate     13.80%  
Prospective effective annual interest rate     23.90%  
Ligand Pharmaceuticals Incorporated [Member] | Common Stock [Member]        
Liability Related To Sale Of Future Royalties And Milestones [Line Items]        
Warrants issued to purchase shars of common stock   867,052    
Warrants, exercise price   $ 17.3    
Ligand Pharmaceuticals Incorporated [Member] | Royalty Purchase Agreement [Member]        
Liability Related To Sale Of Future Royalties And Milestones [Line Items]        
Prospective effective annual interest rate     21.40%  
Ligand Pharmaceuticals Incorporated [Member] | Purchase Agreement [Member]        
Liability Related To Sale Of Future Royalties And Milestones [Line Items]        
Non-cash interest expense     $ 13,200  
Effective annual interest rate     21.00%  
Liability related to sale of future royalties and milestones     $ 63,879  
Percentage of synthetic royalty on worldwide net sales of purchased assets   2.625%    
Percentage reduction in amounts payable upon overall payments due exceeding specified return hurdle   50.00%    
Percentage increase in synthetic royalty based on certain future events   1.00%    
Consideration on sale of purchased assets gross   $ 75,000    
Reimbursable expenses   900    
Time-based option to invest, additional amount   $ 25,000    
Gross proceeds from purchase agreement     $ 75,000  
Ligand Pharmaceuticals Incorporated [Member] | Covered License Agreements [Member] | Purchase Agreement [Member]        
Liability Related To Sale Of Future Royalties And Milestones [Line Items]        
Percentage of sale of development, regulatory and commercial milestone payments eligible to receive   31.875%    
Percentage of royalties receipts   18.75%